At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 10-09 10:05:21 EDT
477.31
+0.40
+0.08%
High483.64Low474.38Vol50.99K
Open477.48D1 Closing476.91Amplitude1.94%
Mkt Cap11.00BTradable Cap6.55BTotal Shares23.06M
T/O24.40MT/O Rate0.37%Tradable Shares13.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
GlobeNewswire  ·  10-06
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  09-30
Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts
TIPRANKS  ·  09-26
HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Dow Jones  ·  09-24
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs
TIPRANKS  ·  09-24
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
MT Newswires Live  ·  09-23
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
Madrigal Pharmaceuticals, Inc. : Citigroup Initiates Coverage with Buy Rating; Price Target $725
THOMSON REUTERS  ·  09-23
Madrigal Pharmaceuticals, Inc. : Citigroup Initiates Coverage with Buy Rating; Price Target $725
Madrigal Pharmaceuticals initiated with a Buy at Citi
TIPRANKS  ·  09-23
Madrigal Pharmaceuticals initiated with a Buy at Citi
Madrigal Pharmaceuticals management to meet with Oppenheimer
TIPRANKS  ·  09-19
Madrigal Pharmaceuticals management to meet with Oppenheimer
Madrigal Grants Inducement Equity Awards to 27 New Hires, Including 2,754 Stock Options Priced at USD 538.71
Reuters  ·  09-17
Madrigal Grants Inducement Equity Awards to 27 New Hires, Including 2,754 Stock Options Priced at USD 538.71
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-17
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  09-17
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharma CEO William John Sibold Disposes of Common Shares Worth $4.16 Million
Reuters  ·  09-12
Madrigal Pharma CEO William John Sibold Disposes of Common Shares Worth $4.16 Million
Madrigal Pharmaceuticals to Present at Cantor Global Healthcare Conference
Reuters  ·  09-02
Madrigal Pharmaceuticals to Present at Cantor Global Healthcare Conference
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Simply Wall St.  ·  08-29
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Market Focus  ·  08-27
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Reuters  ·  08-21
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Simply Wall St.  ·  08-20
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--